Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Foods International CoPMDSF 69 Equity-to-Asset is 0.30 as of Jan. 2026, which is 14% below its 10-year median of 0.35. GuruFocus rates PMDSF with a GF Score™ of 69/100 and a GF Value™ of $10.87. The stock has 5 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Pharma Foods International Co ranks worse than 83.5% on this metric.
Pharma Foods International Co (OTCPK:PMDSF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Pharma Foods International Co Equity-to-Asset Related Terms
Pharma Foods International Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Foods International Co Equity-to-Asset Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Pharma Foods International Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Foods International Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharma Foods International Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Pharma Foods International Co's Equity-to-Asset falls into.
Pharma Foods International Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Foods International Co (PMDSF) has a Equity-to-Asset of 0.30 as of Jan. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Pharma Foods International Co and its competitors. This is 14% below median its historical median of 0.35. Over the past decade, Pharma Foods International Co's Equity-to-Asset has ranged from 0.14 to 0.78. According to the industry distribution chart, Pharma Foods International Co ranks #840 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 83.5%.
Is Pharma Foods International Co's Equity-to-Asset too high?
Pharma Foods International Co's current Equity-to-Asset of 0.30 is 14% below median its 10-year median of 0.35. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 0.78. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Pharma Foods International Co's value of 0.30 is 50% below this industry median. Based on the distribution chart, Pharma Foods International Co ranks #840 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pharma Foods International Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Pharma Foods International Co's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Pharma Foods International Co ranks #840 out of 1006 companies for Equity-to-Asset. This places Pharma Foods International Co in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Pharma Foods International Co's value of 0.30 is 50% below this benchmark. Historically, Pharma Foods International Co's own Equity-to-Asset has ranged from 0.14 to 0.78 over the past decade. While the company's 10-year median is 0.35 vs. the industry median of 0.60, Pharma Foods International Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Foods International Co's current Equity-to-Asset of 0.30 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Pharma Foods International Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Foods International Co's current Equity-to-Asset is 0.30, which is 14% below median its own 10-year median of 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Foods International Co stock overvalued right now?
Pharma Foods International Co (PMDSF) has a current Equity-to-Asset of 0.30. The stock's GF Value™ is $10.87, compared to a current price of $6.40 — trading 41.1% below its estimated fair value. The current Equity-to-Asset is 0.30, which is 14% below median its 10-year median of 0.35 and 50% below the Drug Manufacturers industry median of 0.60. Pharma Foods International Co's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Pharma Foods International Co (PMDSF), the current Equity-to-Asset is 0.30 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Foods International Co (PMDSF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Foods International Co stock appears to be undervalued.
The current stock price of $6.40 is trading 41.1% below its estimated GF Value™ of $10.87.
Key valuation signals for PMDSF:
Equity-to-Asset: 0.30 (14% below median its 10-year median of 0.35)
GF Value™: $10.87 vs. price of $6.40 (41.1% below fair value)
Industry Position: 50% below the Drug Manufacturers median (#840 of 1006)
No single metric tells the full story. See the PMDSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMDSF has been successfully added to your 
